RSRaffaella Scorza

Raffaella Scorza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Raffaella Scorza has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Lorenzo Beretta

    Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy

    6 shared publications
  • Lorenzo Beretta

    Fdn IRCCS Osped Maggiore Policlin, Milan, Italy

    5 shared publications
  • Francesca Cappiello

    4 shared publications
  • L. Beretta

    Referral Centre for Systemic Autoimmune Diseases, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Pace 9, 20122 Milano, Italy

    4 shared publications
  • Alessandro Santaniello

    Fdn IRCCS Osped Maggiore Policlin, Milan, Italy

    3 shared publications
  • Alessandro Santaniello

    Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Via Pace 9, 20122, Milano, Italy

    3 shared publications

Latest Publications

  • Sclerosi Sistemica

    by Carla Garbagnati Crosti, Raffaella Scorza

    • 13 December 2012
      • Vol. 31, 135-9

    Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series.

    by Gaia Montanelli, Lorenzo Beretta, Alessandro Santaniello, Raffaella Scorza

    Scleroderma renal crisis (SRC) is a relative rare yet dramatic event in the history of systemic sclerosis (SSc). Several factors that may precipitate or protect from the development of SRC have been described in previous case-control studies. To date, no attempt has been made to evaluate these factors in an observational fashion. Retrospective data from 410 SSc patients with disease duration <5 years at referral were evaluated in an observational fashion for the development of hypertensive or normotensive SRC within 5 years from the first visit at our centre. Baseline characteristics as well as the use of steroids or dhiydropyridine calcium-channel blockers (CCB) were analysed via the Cox regression method with time-dependent covariates. In the multivariate model the diffuse subset the disease (HR=5.728 CI(95)=2.199-14.918, p<0.001) and the use of prednisone (HR=1.015, CI(95)=1.004-1.026, p=0.006) resulted to be predictors for the development of SRC, with a risk to develop SRC increased by 1.5% for every mg of prednisone/day consumed the trimester prior SRC. Contrariwise, the risk to develop SRC was highly reduced in those who were prescribed CCBs (HR=0.094, CI(95)=0.038-0.236, p<0.001). Steroids exhibits a weak effect on the risk to progress toward SRC in our case series, whilst dhyidrophyridines CCB appeared to be protective against that. Further larger prospective studies are warranted to better define the role of CCB in this setting or as a background therapy for SSc.


  • A 3-factor epistatic model predicts digital ulcers in Italian scleroderma patients

    by Lorenzo Beretta, Alessandro Santaniello, Michael Mayo, Francesca Cappiello, Maurizio Marchini, Raffaella Scorza


    • 14 June 2010
      • Vol. 28, S18-27

    Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches.

    by Lorenzo Beretta, Alessandro Santaniello, Francesca Cappiello, Nitesh V Chawla, Madelon C Vonk, Patricia E Carreira, Yannick Allanore, D A Popa-Diaconu, Marta Cossu, Francesca Bertolotti, et al.

    Systemic sclerosis (SSc) is a multiorgan disease with high mortality rates. Several clinical features have been associated with poor survival in different populations of SSc patients, but no clear and reproducible prognostic model to assess individual survival prediction in scleroderma patients has ever been developed. We used Cox regression and three data mining-based classifiers (Naïve Bayes Classifier [NBC], Random Forests [RND-F] and logistic regression [Log-Reg]) to develop a robust and reproducible 5-year prognostic model. All the models were built and internally validated by means of 5-fold cross-validation on a population of 558 Italian SSc patients. Their predictive ability and capability of generalisation was then tested on an independent population of 356 patients recruited from 5 external centres and finally compared to the predictions made by two SSc domain experts on the same population. The NBC outperformed the Cox-based classifier and the other data mining algorithms after internal cross-validation (area under receiving operator characteristic curve, AUROC: NBC=0.759; RND-F=0.736; Log-Reg=0.754 and Cox= 0.724). The NBC had also a remarkable and better trade-off between sensitivity and specificity (e.g. Balanced accuracy, BA) than the Cox-based classifier, when tested on an independent population of SSc patients (BA: NBC=0.769, Cox=0.622). The NBC was also superior to domain experts in predicting 5-year survival in this population (AUROC=0.829 vs. AUROC=0.788 and BA=0.769 vs. BA=0.67). We provide a model to make consistent 5-year prognostic predictions in SSc patients. Its internal validity, as well as capability of generalisation and reduced uncertainty compared to human experts support its use at bedside. Available at: http://www.nd.edu/~nchawla/survival.xls.


  • Open Access

    A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation

    by Lorenzo Beretta, Marta Cossu, Maurizio Marchini, Francesca Cappiello, Andrea Artoni, Giovanna Motta, Raffaella Scorza

    Introduction: Platelet aggregation may contribute to the pathogenesis of systemic sclerosis: following activation, platelets release significant amounts of serotonin – which promotes vasoconstriction and fibrosis, and further enhances aggregation. The C+1354T polymorphism in the exonic region of the serotonin 2A receptor gene determining the His452Tyr substitution was associated with blunted intracellular responses after serotonin stimulation, and may have a role in susceptibility to scleroderma.Methods: One hundred and fifteen consecutive systemic sclerosis patients and 140 well-matched healthy control individuals were genotyped by sequence-specific primer-PCR for the His452Tyr substitution of the serotonin 2A receptor gene, and associations were sought with scleroderma and its main clinical features. The functional relevance of the His452Tyr substitution was also assessed by evaluating the aggregation of platelet-rich plasma from His452/His452and His452/Tyr452healthy individuals after stimulation with adenosine diphosphate ± serotonin.Results: The T allele of the C+1354T polymorphism was underrepresented in scleroderma patients compared with control individuals (5.2% versus 12.4%,P< 0.001, chi-square test and 1,000-fold permutation test) and its carriage reduced the risk for systemic sclerosis (odds ratio = 0.39, 95% confidence interval = 0.19 to 0.85,P< 0.01). Platelets from His452/Tyr452healthy subjects more weakly responded to serotonin stimulation compared with platelets from His452/His452individuals (3.2 ± 2.6-fold versus 9.6 ± 8.6-fold increase in aggregation,P= 0.017 by Kolmogorov–Smirnov test andP= 0.003 after correction for baseline adenosine diphosphate-induced aggregation values).Conclusion: The His452Tyr substitution may influence susceptibility to systemic sclerosis by altering platelet aggregation in response to serotonin.


  • Effects of aminaftone 75 mg TID on soluble adhesion molecules: A 12-week, randomized, open-label pilot study in patients with systemic sclerosis

    by Raffaella Scorza, Alessandro Santaniello, Giulia Salazar, Stefania Lenna, Silvia Della Bella, Rita Antonioli, Karen Toussoun, Lorenzo Beretta


  • Aminaftone, a Derivative of??4-Aminobenzoic Acid, Downregulates??Endothelin-1 Production in??ECV304 Cells

    by Raffaella Scorza, Alessandro Santaniello, Giulia Salazar, Stefania Lenna, Gualtiero Colombo, Flavia Turcatti, Lorenzo Beretta

    Background and objective: Endothelin-1 (ET-1) plays a central role in the pathogenesis of several vascular diseases. Aminaftone is a drug used for the treatment of capillary disorders but which has a mechanism of action that is not fully understood. We investigated whether aminaftone may exert its effect by interfering with the production of ET-1. Methods: Human ECV304 endothelial cells were incubated with interleukin-1β (IL-1β) 100 IU/mL with or without the addition of increasing concentrations of aminaftone (2, 4 or 6 μg/mL). ET-1 concentrations in surnatants were quantified by enzyme immunoassay kit at 3, 6 and 12 hours. Pre-pro-endothelin-1 (PPET-1) gene expressions were also analysed by real-time polymerase chain reaction (RTPCR) at the same time points. Endothelin-converting enzyme (ECE) activity was also determined. Results: Incubation with IL-1β increased concentrations of ET-1 and PPET-1 relative gene expression. Incubation with aminaftone significantly reduced production of ET-1 in a concentration-dependent manner. A strong direct correlation was found between ET-1 concentrations and PPET-1 relative gene expression, but aminaftone did not influence ECE activity. Conclusion: Aminaftone inhibits ET-1 production in cell cultures by interfering with transcription of the PPET-1 gene. These findings may account for the clinical efficacy of aminaftone in the treatment of capillary disorders and may encourage conduct of further clinical trials.


  • Open Access

    No evidence for a role of the proximal IL‐6 G/C ‐174 single nucleotide polymorphism in Italian patients with systemic sclerosis

    by Lorenzo Beretta, Alessandro Santaniello, Francesca Cappiello, Morena Barili, Raffaella Scorza


  • Proximal interleukin‐10 gene polymorphisms in Italian patients with systemic sclerosis

    by L. Beretta, F. Cappiello, M. Barili, R. Scorza

    Interleukin‐10 (IL‐10) can favour the development of fibrosis by promoting a relative shift towards T helper 2 responses. Three single base pair substitutions in the 5′ flanking region of the IL‐10 gene (G/A −1082, C/T −819 and C/A −592) influence the amount of IL‐10 secreted in cell cultures: the GCC haplotype is associated with an increased production, while the ACC and the ATA haplotypes are associated with intermediate and decreased production. Accordingly, three phenotypes have been individuated: high producers (GCC+/GCC+), medium producers (GCC+/GCC−) and low producers (GCC−/GCC−). We hypothesised that IL‐10 haplotypes and genotypes are differently expressed in patients with systemic sclerosis (SSc) with the limited cutaneous SSc (lcSSc) subset or the diffuse cutaneous SSc (dcSSc) subset. One hundred and sixty‐one unrelated Italian patients with SSc and 94 controls have been included. Their DNA was extracted and stored before being analysed by polymerase chain reaction with sequence‐specific primers. The GCC haplotype is overrepresented in patients with SSc; subjects with dcSSc were the primary contributors to these results (dcSSc: 52.2% vs controls: 37.2%; χ2= 8.519, 2 d.f., corrected P= 0.04). In Scl70‐positive patients, the GCC haplotype increased the likelihood of presenting the dcSSc subset [χ2= 12.56, P < 0.0005; odds ratio (OR) = 3.89, 95% confidence interval (CI95) = 1.69–9.08]; these results were confirmed at the phenotypic level (χ2= 11.67, 2 d.f., P= 0.003). In Scl70‐positve patients, the high‐producing phenotype was associated with poor survival, independently from disease subset and gender (hazard ratio = 9.9, CI95= 1.6–61.27, P < 0.05). The IL‐10 haplotype and genotype associated with high IL‐10 production may alter the susceptibility to SSc and/or its expression, increasing the prognostic value of other well‐known markers of disease severity.